Approval for clinical phase II study in DFU by German health agency PEI

On 27 May 2021 Aposcience AG received the notification of the Paul-Ehrlich-Institut of the approval of the clinical phase II trial in diabetic foot ulcer (DFU), MARSYAS II, for Germany.

Currently, the MARSYAS II trial has regulatory approvals for Austria, Czech Republic, Germany and Poland.